Tenapanor Hydrochloride
- Generic Name
- Tenapanor Hydrochloride
A Phase 1 Study to Examine the Pharmacodynamics of Different AZD1722 Formulations
- First Posted Date
- 2014-09-26
- Last Posted Date
- 2014-09-26
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 18
- Registration Number
- NCT02249936
- Locations
- 🇺🇸
ICON Development Solutions, Omaha, Nebraska, United States
Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of AZD1722 in Healthy Male and Female Japanese Subjects
- First Posted Date
- 2014-06-27
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 83
- Registration Number
- NCT02176252
- Locations
- 🇺🇸
WCCT Global, Cypress, California, United States
To Evaluate the Effect of AZD1722 on the Pharmacokinetics of Oral Midazolam in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2014-05-16
- Last Posted Date
- 2015-09-22
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 65
- Registration Number
- NCT02140268
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
Dose Finding Study to Treat High Phosphate Levels in the Blood.
- First Posted Date
- 2014-03-07
- Last Posted Date
- 2020-09-14
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 162
- Registration Number
- NCT02081534
- Locations
- 🇬🇧
Research Site, London, United Kingdom
AZD1722 Open Label, Absorption Distribution Metabolism and Excretion Study
- First Posted Date
- 2014-02-14
- Last Posted Date
- 2015-09-22
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 26
- Registration Number
- NCT02063386
- Locations
- 🇬🇧
Research Site, London, United Kingdom
The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C)
Phase 2
Completed
- Conditions
- Constipation Predominant Irritable Bowel Syndrome
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-08-15
- Last Posted Date
- 2020-04-08
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 356
- Registration Number
- NCT01923428
A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria
Phase 2
Completed
- Conditions
- Chronic Kidney DiseaseType 2 Diabetes Mellitus
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-05-06
- Last Posted Date
- 2020-05-27
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 154
- Registration Number
- NCT01847092
- Locations
- 🇺🇸
Creekside Endocrine Associates PC, Denver, Colorado, United States
A Study to Evaluate the Safety and Efficacy of RDX5791 for the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS-C)
Phase 2
Completed
- Conditions
- Constipation Predominant Irritable Bowel Syndrome
- Interventions
- First Posted Date
- 2011-04-22
- Last Posted Date
- 2019-10-15
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 186
- Registration Number
- NCT01340053
- Locations
- 🇺🇸
Ardelyx Investigational Site, Lynchburg, Virginia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath